Bristol-Myers Squibb

Bristol-Myers Squibb is among the world’s largest Pharmaceuticals sector businesses in the world. Bristol-Myers Squibb’s employees generate $1.561B in profits on $17.714B of revenue. Global output in the Pharmaceuticals business will likely rise substantially over the next 10 years. Long-term economic growth may lift all boats, but Bristol-Myers Squibb is determined to remain a market leader. Sectoral leadership in the Pharmaceuticals segment takes dedication and consistency, but management seeks out-sized growth.

Bristol-Myers Squibb’s ticker symbol BMY has recently been trading near $31.50 a share. The Bristol-Myers Squibb corporate headquarters in New York, NY predicts Pharmaceuticals profits will satisfy shareholders in search of risk-appropriate returns.

The significance of market volume is sometimes ignored, but with a total market capitalization of $61.994B ensures sufficient liquidity. With a beta of 1.19, the company is more volatile than the market as a whole. When the average equity moves higher, Bristol-Myers Squibb moves more aggressively.